STK11 and large cell neuroendocrine carcinoma: LCNECs are considered intermediate entities between NSCLC and SCLC, harboring frequent LUAD-associated genomic alterations, but exhibiting NE features.45,106 Interestingly, recent molecular characterizations of these rare tumors converge into a classification driven by genomic events, which distinguishes SCLC-like LCNEC, enriched for RB1 mutations, and NSCLC-like LCNEC, enriched for STK11 and KEAP1 mutations.